Table 4.
Predictive factors related to the development of HCC after DAA therapy on Cox proportional hazard analysis
| Characteristics | Category | Hazard ratio | 95% Confidence interval | P‐value |
|---|---|---|---|---|
| Development of HCC | ||||
| History of previous HCC | 1: No 2: Yes |
10.634 | 4.132–27.369 | 0.001 |
| Total bilirubin (mg/dL) | 1: <1.0 2: ≥1.0 |
4.189 | 1.656–10.597 | 0.002 |
| Age (years) | 1: <75 2: ≥75 |
4.638 | 1.634–13.161 | 0.004 |
| Occurrence of HCC | ||||
| Liver stiffness (m/s) | 1: <1.73 2: ≥1.73 |
8.350 | 1.618–43.09 | 0.011 |
DAA, direct‐acting antiviral; HCC, hepatocellular carcinoma.